• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 13th June 2017

OHE at HTAi 2017: Meet the Team

The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will attend and participate…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will attend and participate in the conference.

The HTAi Annual Meeting 2017 will be held in Rome, Italy, 17-21st June 2017. The theme of the meeting is Towards an HTA Ecosystem: From Local Needs to Global Opportunities. Several members of the OHE team will be attending and participating in the conference. We would welcome the opportunity to meet with you to discuss our research.

You will find members of the OHE team presenting at the following sessions:

Panel: Incorporating Multiple Criteria into Health Technology Assessment: Opportunities and Challenges

OHE Authors: Nancy Devlin

Time & Date: Monday 19th June, 11:30

Multi-criteria decision analysis (MCDA) has been suggested as an option to enable rational, transparent decision making for health technology assessment (HTA). However, there are many challenges with using MCDA for HTA.

Nancy Devlin will present on the extent to which the use of structured approaches to the use of multiple criteria in HTA is consistent with the extra welfarist foundations for HTA, including discussion of the need for consistency of criteria/weights, and the implications for how we address opportunity cost (i.e., what it all means for the threshold/judgements about value for money) in a multiple criteria decision context.

Symposia: Resistance to Antimicrobials: A Call for Multi- Disciplinary Action: How Can HTA Help?

OHE Authors: Adrian Towse

Time & Date: Monday 19th June, 13:00

Resistance to antimicrobials and a lack of new effective drugs is a wide-spreading medical threat. Challenges include finding a balance between the need (i) for newly discovered and cost effective therapies and (ii) for good stewardship to preserve new antibiotics and slow down the build-up of resistance. Ensuring good use of HTA is key. Incorporating public health elements of value, however, can pose a challenge for HTA bodies. Adrian will focus on ten potential elements of value, four familiar ones and six new. These are highlighted in a recent OHE-AIM report.

Presentation: Extrapolation From Progression Free Survival To Overall Survival In Oncology

OHE Authors: Karla Hernandez-Villafuerte, Alastair Fischer

Time & Date: Monday 19th June, 18:00

Progression free survival (PFS) is the most commonly used surrogate outcome in cancer. This work aims at analysing the methods used to extrapolate from PFS to overall survival (OS) in the field of oncology as well as at determining the key limitations, weaknesses and gaps in the current literature and methods used to test PFS surrogacy.

Presentation: MCDA to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab

OHE Authors: Martina Garau, Grace Hampson, Nancy Devlin

Time & Date: Monday 19th June, 16:30

This study applied an MCDA approach (EVIDEM) to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians, and payers) in Italy and to assess the value of obinutuzumab for rituximab-refractory iNHL. This study provides an example of how stakeholders’ views can be quantified and captured in decision making in an explicit way.

Presentation: Advanced Therapy Medicinal Products: Are Current HTA Methods Suitable?

OHE Authors: Grace Hampson, Adrian Towse

Time & Date: Tuesday 20th June, 16:30

High prices mean that HTA and reimbursement decisions for advanced therapy medicinal products (ATMPs) are challenging for payers and manufacturers, even when the therapies are expected to offer good value for money. We present a review of one example, from the UK’s National Institute for Health and Care Excellence (NICE), who commissioned an external organisation to undertake a mock appraisal of a hypothetical ATMPs using standard methods.

Presentation: Access to Orphan Drugs in the UK and Other European Countries

OHE Authors: Bernarda Zamora, Martina Garau, Francois Maignen, Phill O’Neill

Time & Date: Tuesday 20th June, 18:00

This study compares the availability and access to orphan medicinal products in the UK (England, Scotland and Wales), France, Germany, Italy and Spain. Orphan drugs are authorised in all EU countries, however their access is restricted by reimbursement policies (especially in the UK, Italy and Spain). 

Panel: Value Assessment of Multi-Indication Products: Practical Solutions and Steps

OHE Authors: Adrian Towse

Time & Date: Wednesday 21st June, 08:30

Increasing numbers of new drugs (notably biologicals in oncology) have several indications. How should HTA bodies, drug developers and payers behave to get the maximum use of effective products at acceptable prices and in sustainable way for technology investors? The objective is to agree an efficient mechanism for HTA bodies, payers and manufacturers to get the maximum use of products with multiple effective indications at prices that reflect value to the health care system and are sustainable for technology R&D investors. Adrian Towse will introduce the issue and moderate the discussion.

For further information on any of these presentations please contact the OHE authors via our Meet the Team webpage.

  • Health Technology Assessment…
  • Events

Related News

MicrosoftTeams-image-6_0
  • News
  • June 2022

OHE’s 60th Anniversary Party – Celebrating Our Achievements and Looking Forward

Read more
  • News
  • September 2020

Cornerstones of ‘Fair’ Drug Coverage

Read more
  • News
  • September 2020

Assessing the Productivity Value of Vaccines in Health Technology Assessment: Worth a Shot?

Read more
  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!